Based on the successful results of a randomized clinical trial, the anti-CTLA-4 monoclonal antibody ipilimumab became the first ICI approved for cancer treatment and was used in the setting of advanced melanoma [32,33]. The gene discussed is CTLA4; the disease is melanoma.